AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16788389 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention program along with usual rehabilitation care
Number of subjects: 155
Study 16788389 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation care alone
Number of subjects: 155
Study 12590012 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hormonal replacement therapy (LD‐HRT), 17beta‐estradiol (1 mg/day) and norethisterone acetate (0.5 mg/day)
Number of subjects: 50
Study 12590012 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplement (controls)
Number of subjects: 50
Study 10383370 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.0-mm external bore nasogastric tube
Number of subjects: 17
Study 10383370 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.85-mm external bore nasogastric tube
Number of subjects: 17
Study 10383370 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 17
Study 7631298 — intervention group
Group type: COMPARATOR
Intervention: Randomised treatment
Number of subjects: 0
Study 1849536 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake
Number of subjects: 100
Study 1849536 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake
Number of subjects: 100
Study 1849536 — intervention group
Group type: COMPARATOR
Intervention: Crossover protocol of sodium intake
Number of subjects: 100
Study 6756936 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg plus codeine 20 mg
Number of subjects: 266
Study 6756936 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg plus codeine 30 mg
Number of subjects: 266
Study 6756936 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg plus codeine 40 mg
Number of subjects: 266
Study 6756936 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 500 mg
Number of subjects: 266
Study 29700813 — intervention group
Group type: EXPERIMENTAL
Intervention: QbTest report provided immediately (QbOpen group)
Number of subjects: 267
Study 29700813 — intervention group
Group type: COMPARATOR
Intervention: Assessment as usual without QbTest report (QbBlind group)
Number of subjects: 267
Study 29700813 — intervention group
Group type: EXPERIMENTAL
Intervention: Health economic analysis
Number of subjects: 267
Study 28736511 — intervention group
Group type: EXPERIMENTAL
Intervention: MSM (OptiMSM®) at 3 g/day for 21 days prior to the race and for two days after (23 total)
Number of subjects: 22
Study 28736511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28736511 — intervention group
Group type: EXPERIMENTAL
Intervention: MSM (OptiMSM®)
Number of subjects: 22
Study 25319739 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4 index
Number of subjects: 631
Study 25319739 — intervention group
Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 631
Study 25319739 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4 index (overestimated score)
Number of subjects: 631
Study 23295321 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor feedback
Number of subjects: 99
Study 23295321 — intervention group
Group type: COMPARATOR
Intervention: Control (no instructor feedback)
Number of subjects: 99
Study 21942465 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg twice a day
Number of subjects: 158
Study 21942465 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg thrice a day
Number of subjects: 158
Study 18837809 — intervention group
Group type: EXPERIMENTAL
Intervention: Home videoconferencing
Number of subjects: 0
Study 18837809 — intervention group
Group type: COMPARATOR
Intervention: Telephone calls
Number of subjects: 0
Study 15668218 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural modification group (BM)
Number of subjects: 293
Study 15668218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundamental motor skills group (FMS)
Number of subjects: 293
Study 15668218 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined BM and FMS group
Number of subjects: 293
Study 15668218 — intervention group
Group type: COMPARATOR
Intervention: Control (usual classroom lessons)
Number of subjects: 293
Study 12829141 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative RT combined with mitomycin C (15 mg/m2 after 10 Gy) and bleomycin (5 mg twice a week during RT to a total of 70 mg)
Number of subjects: 114
Study 12829141 — intervention group
Group type: COMPARATOR
Intervention: Postoperative RT alone
Number of subjects: 114
Study 12829141 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative RT combined with mitomycin C and bleomycin
Number of subjects: 114
Study 10817348 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (120 mg/m2, i.v. bolus every 3 weeks)
Number of subjects: 127
Study 8664976 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I (10 micrograms.kg‐1.h‐1 sc for 5 days) in healthy subjects
Number of subjects: 16
Study 8664976 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I (10 micrograms.kg‐1.h‐1 sc for 7 days) in subjects with GH and TSH deficiency
Number of subjects: 16
Study 8664976 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (GH) alone (2 IU m‐2 sc q.i.d.)
Number of subjects: 16
Study 8664976 — intervention group
Group type: COMPARATOR
Intervention: GH plus IGF-I
Number of subjects: 16
Study 2052337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil, 1 gm/day
Number of subjects: 116
Study 2052337 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin, 250 mg four times a day
Number of subjects: 116
Study 6619055 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin (300 mg/kg/day) alone
Number of subjects: 14
Study 6619055 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (300 mg/kg/day) and tobramycin (7 mg/kg/day) iv
Number of subjects: 14
Study 6619055 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin and tobramycin
Number of subjects: 14
Study 6619055 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 14
Study 6619055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 14
Study 31545507 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 200 mg once daily
Number of subjects: 230
Study 31545507 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 800 mg once daily
Number of subjects: 230
Study 30577903 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent/Youth intervention
Number of subjects: 532
Study 30577903 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Only intervention
Number of subjects: 532
Study 30577903 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (Treatment as usual)
Number of subjects: 532
Study 28408635 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction group (RES, n=8) - subjects slept two-thirds of normal sleep time for 8 days and 8 nights
Number of subjects: 17
Study 28408635 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, n=9) - subjects allowed to sleep their usual sleep time
Number of subjects: 17
Study 28408635 — intervention group
Group type: COMPARATOR
Intervention: Both groups (RES and CON) during REM sleep
Number of subjects: 17
Study 28408635 — intervention group
Group type: EXPERIMENTAL
Intervention: After 8 days of moderate sleep deprivation
Number of subjects: 17
Study 26975625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance Movement Therapy (DMT)
Number of subjects: 139
Study 26975625 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study 25131129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A‐based immunosuppression
Number of subjects: 0
Study 25131129 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus‐based immunosuppression
Number of subjects: 0
Study 22492517 — intervention group
Group type: COMPARATOR
Intervention: NIHSS at 1 to 3 hours
Number of subjects: 312
Study 22492517 — intervention group
Group type: COMPARATOR
Intervention: NIHSS at 24 hours
Number of subjects: 312
Study 22492517 — intervention group
Group type: COMPARATOR
Intervention: NIHSS at 90 days
Number of subjects: 312
Study 22492517 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous improvement from 1-3 hours to 24 hours
Number of subjects: 312
Study 22492517 — intervention group
Group type: COMPARATOR
Intervention: NIHSS scores associated with final modified Rankin Scale of 2
Number of subjects: 312
Study 22492517 — intervention group
Group type: COMPARATOR
Intervention: Correlation between NIHSS and final modified Rankin Scale
Number of subjects: 312
Study 20175431 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG 270 mg
Number of subjects: 8
Study 20175431 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg
Number of subjects: 8
Study 20175431 — intervention group
Group type: COMPARATOR
Intervention: Placebo 270 mg
Number of subjects: 8
Study 20175431 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG 270 mg + Caffeine 3 mg/kg
Number of subjects: 8
Study 17471993 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (OT)
Number of subjects: 20
Study 17471993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ozone pretreatment)
Number of subjects: 20
Study 15955104 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 0
Study 15955104 — intervention group
Group type: COMPARATOR
Intervention: Normal skin
Number of subjects: 0
Study 15955104 — intervention group
Group type: COMPARATOR
Intervention: Non-lesional psoriatic skin
Number of subjects: 0
Study 15955104 — intervention group
Group type: COMPARATOR
Intervention: Lesional psoriatic skin
Number of subjects: 0
Study 12095466 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic nerve blocks
Number of subjects: 0
Study 12095466 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional, anesthetic, and ablative techniques
Number of subjects: 0
Study 9883103 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity rating
Number of subjects: 128
Study 9883103 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionality rating
Number of subjects: 128
Study 9883103 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Activity rating
Number of subjects: 128
Study 9883103 — intervention group
Group type: EXPERIMENTAL
Intervention: Memorability rating
Number of subjects: 128
Study 9883103 — intervention group
Group type: COMPARATOR
Intervention: Control studies on Familiarity dimension
Number of subjects: 128
Study 7611390 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein diet (1.62 +/- 0.02 g protein.kg-1.day-1)
Number of subjects: 12
Study 7611390 — intervention group
Group type: COMPARATOR
Intervention: Lower protein diet (0.80 +/- 0.02 g protein.kg-1.day-1)
Number of subjects: 12
Study 7611390 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets during resistance training
Number of subjects: 12
Study 2223335 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 0.01 mg kg‐1 administered 5 min after midazolam
Number of subjects: 0
Study 2223335 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 2 mg and 5 mg i.v.
Number of subjects: 0
Study 2223335 — intervention group
Group type: COMPARATOR
Intervention: Flumazenil alone
Number of subjects: 0
Study 28988 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 20
Study 28988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 20
Study 28988 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline-Ephedrine combination
Number of subjects: 20
Study 28988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine-Butabarbital combination
Number of subjects: 20
Study 28988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28988 — intervention group
Group type: EXPERIMENTAL
Intervention: Butabarbital
Number of subjects: 20
Study 28988 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaifenesin
Number of subjects: 20
Study 31690298 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization education program (individual education sessions involving fathers)
Number of subjects: 225
Study 31690298 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization education program
Number of subjects: 225
Study 28545998 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 4 mg/kg
Number of subjects: 94
Study 28545998 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 1 mg/kg
Number of subjects: 94
Study 26506062 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training group (n = 16)
Number of subjects: 32
Study 26506062 — intervention group
Group type: COMPARATOR
Intervention: Warm-up (n = 32)
Number of subjects: 32
Study 23746392 — intervention group
Group type: EXPERIMENTAL
Intervention: Long backboard (LBB)
Number of subjects: 60
Study 23746392 — intervention group
Group type: COMPARATOR
Intervention: Vacuum mattress splint (VMS)
Number of subjects: 60
Study 21465518 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment with assessment of bone marrow cytology on day 6
Number of subjects: 164
Study 19781835 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1255
Study 19781835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study 16709019 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of the human‐murine chimeric mAb Ch81C6 labeled with the 123I tracer via convection-enhanced delivery (CED)
Number of subjects: 0
Study 16709019 — intervention group
Group type: COMPARATOR
Intervention: Intratumoral injection of the human‐murine chimeric mAb Ch81C6 labeled with the 123I tracer via bolus injection
Number of subjects: 0
Study 15305197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer genetic counselling at five UK centres
Number of subjects: 256
Study 11781670 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral formula (group I)
Number of subjects: 74
Study 11781670 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterotropic peptide-based formula enriched with n-3 fatty acids (group II)
Number of subjects: 74
Study 9323063 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise training program (n=39)
Number of subjects: 77
Study 9323063 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=38)
Number of subjects: 77
Study 8228934 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-dose vaccination scheme starting at month 3 (months 3, 4, 5, and 11)
Number of subjects: 162
Study 8228934 — intervention group
Group type: COMPARATOR
Intervention: Three-dose vaccination scheme starting at birth (months 0, 1, and 6)
Number of subjects: 162
Study 8228934 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-dose vaccination scheme starting at birth (months 0, 1, 2, and 11)
Number of subjects: 162
Study 2878016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined H1 (diphenhydramine hydrochloride) and H2 (cimetidine) histamine antagonists
Number of subjects: 10
Study 2878016 — intervention group
Group type: COMPARATOR
Intervention: H1 antagonist (diphenhydramine hydrochloride) alone
Number of subjects: 10
Study 28655271 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) and supervised exercises
Number of subjects: 143
Study 28655271 — intervention group
Group type: COMPARATOR
Intervention: Sham rESWT and supervised exercises
Number of subjects: 143
Study 28655271 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) and supervised exercises (subgroup analysis)
Number of subjects: 143
Study 26682914 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple-step maneuver (SSM)
Number of subjects: 344
Study 26682914 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-step maneuver (MSM)
Number of subjects: 344
Study 25487932 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injection (15 IU to 45 IU, average 31.2±13.9 IU) plus conventional physical therapy
Number of subjects: 37
Study 25487932 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (PY)
Number of subjects: 37
Study 22385946 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed group (GDS ≥10)
Number of subjects: 0
Study 22385946 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed group (GDS <10)
Number of subjects: 0
Study 22385946 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (as a predictor)
Number of subjects: 0
Study 20618883 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g cholestyramine powder
Number of subjects: 42
Study 20618883 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g cholestyramine powder
Number of subjects: 42
Study 20618883 — intervention group
Group type: COMPARATOR
Intervention: Control drink powder
Number of subjects: 42
Study 18689377 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h recall
Number of subjects: 157
Study 18689377 — intervention group
Group type: COMPARATOR
Intervention: 3-d weighed food records
Number of subjects: 157
Study 15747157 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM
Number of subjects: 20
Study 15747157 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD
Number of subjects: 20
Study 15747157 — intervention group
Group type: COMPARATOR
Intervention: Comparison of DCM and CAD
Number of subjects: 20
Study 12051571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexloxiglumide 100 mg
Number of subjects: 12
Study 12051571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexloxiglumide 200 mg
Number of subjects: 12
Study 12051571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexloxiglumide 400 mg
Number of subjects: 12
Study 12051571 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dosing of Dexloxiglumide 100 mg
Number of subjects: 12
Study 12051571 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dosing of Dexloxiglumide 200 mg
Number of subjects: 12
Study 12051571 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dosing of Dexloxiglumide 400 mg
Number of subjects: 12
Study 12051571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexloxiglumide (all doses)
Number of subjects: 12
Study 10420110 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I diabetes
Number of subjects: 75
Study 10420110 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II diabetes
Number of subjects: 75
Study 10420110 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 75
Study 8789518 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who were told about the contents of a deceptive box (intervention group)
Number of subjects: 121
Study 8789518 — intervention group
Group type: COMPARATOR
Intervention: Children who saw inside the box (control group)
Number of subjects: 121
Study 8789518 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative procedure (intervention)
Number of subjects: 121
Study 2248124 — intervention group
Group type: EXPERIMENTAL
Intervention: Successfully restrained drinkers (light drinkers)
Number of subjects: 0
Study 2248124 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessfully restrained drinkers (heavy drinkers)
Number of subjects: 0
Study 2248124 — intervention group
Group type: COMPARATOR
Intervention: Unrestrained drinkers
Number of subjects: 0
Study 7192147 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoergic drugs (3 stimulants)
Number of subjects: 40
Study 6405838 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative total parenteral nutrition (TPN)
Number of subjects: 57
Study 6405838 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN-5-FU combination
Number of subjects: 57
Study 6405838 — intervention group
Group type: COMPARATOR
Intervention: Non-TPN-5-FU
Number of subjects: 57
Study 6405838 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN-5-FU
Number of subjects: 57
Study 31921171 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus TTR > 78%
Number of subjects: 1241
Study 31921171 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus TTR < 78%
Number of subjects: 1241
Study 31921171 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus TTR
Number of subjects: 1241
Study 29032574 — intervention group
Group type: EXPERIMENTAL
Intervention: Submerged healing protocol
Number of subjects: 40
Study 29032574 — intervention group
Group type: COMPARATOR
Intervention: Transmucosal healing protocol
Number of subjects: 40
Study 29032574 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 26797725 — intervention group
Group type: EXPERIMENTAL
Intervention: Body scan mindfulness meditation (MM)
Number of subjects: 102
Study 26797725 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow breathing (SB) with a biofeedback device
Number of subjects: 102
Study 26797725 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful awareness of the breath with an intention to slow the breath (MM+SB)
Number of subjects: 102
Study 26797725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting quietly (SQ)
Number of subjects: 102
Study 26797725 — intervention group
Group type: COMPARATOR
Intervention: Meditation arms (MM, SB, MM+SB)
Number of subjects: 102
Study 26797725 — intervention group
Group type: EXPERIMENTAL
Intervention: MM compared with MM+SB and SB
Number of subjects: 102
Study 26797725 — intervention group
Group type: EXPERIMENTAL
Intervention: MM, MM+SB, and SQ
Number of subjects: 102
Study 26797725 — intervention group
Group type: EXPERIMENTAL
Intervention: MM
Number of subjects: 102
Study 24393287 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational intervention for delirium
Number of subjects: 0
Study 22566588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg
Number of subjects: 13
Study 22566588 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir 50 mg
Number of subjects: 13
Study 20439216 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (walking 10,000 steps per day)
Number of subjects: 36
Study 17645681 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-G based algorithm
Number of subjects: 1433
Study 16163514 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral Ring Allograft (FRA)
Number of subjects: 78
Study 16163514 — intervention group
Group type: COMPARATOR
Intervention: Titanium Cage (TC)
Number of subjects: 78
Study 12322788 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine/Diltiazem/Vitamin E
Number of subjects: 62
Study 12322788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 10447324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacolene (4 g at start and 2 g 4 hourly until cessation of diarrhoea)
Number of subjects: 78